Open AccessThe RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma
Author(s) -
Panzeri Valentina,
Manni Isabella,
Capone Alessia,
Naro Chiara,
Sacconi Andrea,
Di Agostino Silvia,
Latouliere Luisa,
Montori Andrea,
Pilozzi Emanuela,
Piaggio Giulia,
Capurso Gabriele,
Sette Claudio
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12847
Subject(s) - cancer research , gene knockdown , biology , gemcitabine , pancreatic cancer , cell cycle , cyclin dependent kinase 6 , rna binding protein , cancer , cell growth , rna , cyclin d1 , gene , genetics
RNA dysregulation is a hallmark of most human cancers, including PDAC. We identify the RNA‐binding protein MEX3A as prognostic factor in PDAC. MEX3A regulates stability of transcripts for cell cycle proteins, such as CDK6, and promotes cell cycle progression and resistance to chemotherapeutic treatments.